ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 89 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $62 | -36.1% | 12,918 | +0.5% | 0.00% | – |
| Q2 2023 | $97 | +67.2% | 12,860 | -0.2% | 0.00% | – |
| Q1 2023 | $58 | -60.0% | 12,883 | 0.0% | 0.00% | – |
| Q4 2022 | $145 | -99.9% | 12,883 | -0.1% | 0.00% | – |
| Q3 2022 | $123,000 | +18.3% | 12,894 | +0.6% | 0.00% | – |
| Q2 2022 | $104,000 | -52.1% | 12,820 | -0.2% | 0.00% | – |
| Q1 2022 | $217,000 | -21.4% | 12,850 | +0.1% | 0.00% | – |
| Q4 2021 | $276,000 | -86.7% | 12,837 | -54.5% | 0.00% | -100.0% |
| Q3 2021 | $2,083,000 | +35.0% | 28,199 | -0.1% | 0.00% | 0.0% |
| Q2 2021 | $1,543,000 | -12.1% | 28,216 | +18.5% | 0.00% | 0.0% |
| Q1 2021 | $1,756,000 | +13.1% | 23,811 | +32.2% | 0.00% | 0.0% |
| Q4 2020 | $1,553,000 | +835.5% | 18,011 | +309.3% | 0.00% | – |
| Q3 2020 | $166,000 | – | 4,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |